Animalcare Group: Investing In Product Development
Edison | Apr 24, 2014 01:00AM ET
Animalcare Group Plc (ANCR.LSE) is increasing its investment in new product development as it uses its balance sheet and operational cash flow to improve its product portfolios. The strategy of exiting low-margin and commoditising segments and investing in defensible, higher value-adding products is wise, although the benefits are not expected to accrue until after 2017. The current valuation has yet to capture the potential of this approach.
The animal health market shares many characteristics with its human counterpart but the success factors are subtly different, with financial muscle and global reach being less critical. Nonetheless, the competitive pressures are rising and the importance of having a portfolio of differentiated and value-adding products is growing. Animalcare is pursuing a strategy of de-emphasising the low-margin (and commoditising) segments and investing in new product development.
h3 H114 results highlight strength of current operations/h3H114 results showed revenues up 5.9% from £6.1m to £6.5m, driven by a 10.7% increase in Licensed Veterinary Medicines sales (up from £3.6m to £4.0m) and a 5.6% rise in Companion Animal Identification (from £1.1m to £1.2m) which more than offset the 6.5% decline in Animal Welfare (from £1.4m to £1.3m). Underlying operating profit dipped by 2.9% from £1.5m to £1.4m, with underlying EPS down by 5.2% from 5.8p to 5.5p. The interim dividend was maintained at 1.5p.
h3Internal resources are sufficient to fund pipeline/h3
Despite the rise in working capital, mainly in inventories to safeguard key product lines, Animalcare remains nicely cash generative, with an operating cash flow of £0.9m (H113: £1.3m) and the net cash increased from £3.0m to £3.6m. The strong balance sheet and operational cash flow should allow management to fund the increased investment in the development pipeline organically.
h3Valuation: Future growth potential yet to be priced in/h3
The greater investment in R&D in the near-term means Animalcare’s earnings multiples fail to reflect the value expected to be generated. Our previous valuation of £40.0m was based on an average of DCF and peer-group earnings multiples; however we have expanded our DCF model and are using the peer multiples as a reality check. The DCF valuation is results in a valuation of £41.5m (up 4%).
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below
/h3
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.